ā Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million ā ā Extends Rallybio Cash Runway to Mid-2027 ā The REV102 program originated from a joint venture ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most promising penny stocks under $5 to buy. On February 25, Recursion Pharmaceuticals reported its financial results for Q4 and the full ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Recursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Recursion said today it is eliminating approximately 20% of its workforceāabout 160 jobsāin a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...
SALT LAKE CITY, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates ...
Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated tar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results